Company Description
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.
It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally.
The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States.
The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 20,270 |
| CEO | Thomas Appio |
Contact Details
Address: 2150 St. ElzEar Boulevard West Laval, QC H7L 4A8 Canada | |
| Phone | 514 744 6792 |
| Website | bauschhealth.com |
Stock Details
| Ticker Symbol | BHC |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000885590 |
| CUSIP Number | 071734107 |
| ISIN Number | CA0717341071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas J. Appio | Chief Executive Officer and Director |
| Seana Carson | Executive Vice President and General Counsel |
| Jean-Jacques Charhon | Executive Vice President and Chief Financial Officer |
| Mirza Dautbegovic | Executive Vice President and Chief Operating Officer |
| Garen Sarafian | Vice President and Head of Investor Relations |
| Kathleen Fitzpatrick | Executive Vice President and Chief Human Resources and Communications Officer |
| Cees Heiman | Senior Vice President of Europe and Canada |
| Donald Pearl | Senior Vice President of Ortho Dermatologics |
| Jiny Kim M.B.A. | Senior Vice President of Solta Medical |
| Aimee J. Lenar | Executive Vice President of US Pharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 1, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Sep 20, 2024 | SD | Form - SD |
| Sep 6, 2024 | 144 | Filing |
| Aug 30, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Aug 19, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 1, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | 8-K | Current Report |